The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by RIFKIN, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by RIFKIN, A.
Related Collections
* Behavior Therapy
* Cognitive Therapy
* Miscellaneous Somatic Therapies
* Antidepressants
* Anxiolytics
Am J Psychiatry 158:1165, July 2001
© 2001 American Psychiatric Association


Letter to the Editor

Comparing Psychotherapy and Pharmacotherapy

ARTHUR RIFKIN, M.D.
Glen Oaks, N.Y.

To the Editor: The review by Dr. Klein concerning psychotherapy and pharmacotherapy for the treatment of some conditions elegantly showed that studies comparing cognitive behavior therapy and pharmacotherapy for severe depression have not demonstrated that cognitive behavior therapy equals or surpasses drug treatment. The reader might then infer that this conclusion does not apply to nonsevere depression, especially since the APA practice guideline on this topic (1) supports the use of psychotherapy as acceptable treatment for nonsevere depression. However, if one agrees with Dr. Klein, as I do, that a pill placebo control is necessary for comparing psychotherapy and drug therapy in order to determine that the sample includes subjects who were responsive to drug treatment, then the conclusion that Dr Klein drew for severe depression should apply to nonsevere depression: viz, there are insufficient data to conclude that psychotherapy equals or surpasses drug treatment.

The methodological difficulties of robustly testing this question indicate that we need large multisite studies to ensure expert pharmacotherapy and psychotherapy. Considering the enormous use of psychotherapy, it seems odd that in the 21st century we still lack good evidence for its efficacy for the many mental disorders for which we have substantial, pivotal evidence for the efficacy of drug treatment. I cannot imagine that the proponents of psychotherapy would object to such studies. We cannot depend on drug companies to fund such studies (although that would be nice), so that leaves it up to the National Institute of Mental Health. Perhaps we need a Food and Drug Administration (FDA) counterpart for psychotherapy. Doesn’t the public deserve to know that psychotherapy is safe and effective and how it compares to drug treatment?

Reference

  1. American Psychiatric Association: Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993; 150(April suppl)




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by RIFKIN, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by RIFKIN, A.
Related Collections
* Behavior Therapy
* Cognitive Therapy
* Miscellaneous Somatic Therapies
* Antidepressants
* Anxiolytics


Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org